ArticleTargeted oncology2017

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.

Trisha M Wise-Draper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.